Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25297543 | 0.99 | GRIA2 (0.40) | EGLN1GRIA2SCN3AGAAMAPT | |
| Hydrochloric Acid SCHEMBL30543105 | 0.99 | GRIA2 (0.40) | EGLN1GRIA2SCN3AGAAMAPT | |
| Hydrochloric Acid SCHEMBL25297542 | 0.99 | GRIA2 (0.40) | EGLN1GRIA2SCN3AGAAMAPT | |
| SCHEMBL16268692 | 0.76 | EGLN1 (0.43) | EGLN1GRIA2GAAMAPT | |
| SCHEMBL31651974 | 0.76 | EGLN1 (0.43) | EGLN1GRIA2GAAMAPT | |
| SCHEMBL30543100 | 0.76 | EGLN1 (0.43) | EGLN1GRIA2GAAMAPT | |
| SCHEMBL25290515 | 0.75 | PNMT (0.54) | ADRA2APNMT | |
| Hydrochloric Acid SCHEMBL32677093 | 0.75 | EGLN1 (0.42) | EGLN1GRIA2GAAMAPT | |
| SCHEMBL25255240 | 0.75 | PNMT (0.54) | ADRA2APNMT | |
| Hydrochloric Acid SCHEMBL16267702 | 0.75 | EGLN1 (0.42) | EGLN1GRIA2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | ELI LILLY AND COMPANY | 2023-11-30 | — | — | US | disclosed |
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | ELI LILLY AND COMPANY | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | HTR1D, ADRA1D, HTR1A | EGLN1 3792/4885GRIA2 186/4885SCN3A 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.